ASCO Abstract #10504. Contrary to what many oncologists（肿瘤学家） had thought, a tumor¹ suppressor protein known as PTEN does not reduce the effectiveness of the breast cancer drug Herceptin, according to a study by Mayo Clinic and North Central Cancer Research Group (NCCTG) investigators². The study, which looked at tumors from 1,802 patients enrolled⁴ in the NCCTG N9831 clinical trial, found that patients with HER2-positive breast cancer and had either a loss of PTEN functioning or normal PTEN activity did equally well when Herceptin was added to chemotherapy to prevent breast cancer recurrence⁵. VIDEO ALERT: Additional audio and video resources are available at the Mayo Clinic News Blog. Password: perez

The researchers presented their findings during the American Society of Clinical Oncology Annual Meeting in Chicago.

"This is the largest study to date evaluating PTEN's presence or loss in the context of antiHER2 therapy, and we found no connection," says the study's lead investigator³, oncologist Edith Perez, M.D., director of the Breast Clinic at Mayo Clinic in Jacksonville, Fla., and the Serene⁶ M. and Frances C. Durling Professor. "Our research team is very pleased to be able to test an important question in treatment of breast cancer and arrive at a definitive⁷ answer."

The researchers stained the samples for PTEN expression and linked that data with disease-free survival. They found that PTEN status did not impact disease-free survival significantly; there was only a slightly greater benefit of adding Herceptin for patients with PTEN-tumors.

Preclinical studies and some small patient studies had suggested that tumors with loss of PTEN expression would not benefit from Herceptin, Dr. Perez says. As a result, investigators were considering using PTEN biomarkers in clinical studies as a test of Herceptin resistance, and patients who tested positive for PTEN loss might then be offered other therapies, or invited to participate in clinical trials.

"We have all been interested in biomarkers that predict for benefit to antiHER2 therapy," Dr. Perez says, "but PTEN is not one that we should pursue（追赶，继续） further, based on our rigorous（严格的） analysis."

The tumor samples examined in the study came from NCCTG N9831, a phase III randomized, multicenter clinical trial that tested adjuvant（辅助的） Herceptin given with, or following, chemotherapy（化学疗法） with paclitaxel（紫杉醇） , compared with chemotherapy alone.